gr 127935 has been researched along with Glioma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gommeren, W; Haegeman, G; Heylen, L; Lesage, AS; Leysen, JE; Luyten, WH; Schotte, A; Van de Weyer, I; Van Gompel, P; Vanhoenacker, P; Wouters, R | 1 |
| John, GW; Le Grand, B; Panissié, A; Pauwels, PJ | 1 |
2 other study(ies) available for gr 127935 and Glioma
| Article | Year |
|---|---|
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
Topics: Animals; Benzopyrans; Cattle; Cloning, Molecular; Glioma; HeLa Cells; Humans; Mice; Migraine Disorders; Propylamines; Protein Binding; Pyrimidines; Radioligand Assay; Receptors, Serotonin; Serotonin Receptor Agonists; Signal Transduction; Tritium; Tumor Cells, Cultured; Vasoconstrictor Agents | 1996 |
Activation of recombinant h 5-HT1B and h 5-HT1D receptors stably expressed in C6 glioma cells produces increases in Ca2+-dependent K+ current.
Topics: Animals; Calcium; Cyclic AMP; Dose-Response Relationship, Drug; Glioma; Oxadiazoles; Piperazines; Potassium; Potassium Channels; Rats; Receptors, Serotonin; Recombinant Proteins; Serotonin Antagonists; Sumatriptan; Tumor Cells, Cultured | 1998 |